|
|
|
Score: 97 |
 |
| AHFS Drug Information 2023 |
|
ISBN: 978-1-58528-706-2,
3479 pages,
Soft Cover
ISBN-10: 1-58528-706-7 |
|
| Copyright: |
2023 |
|
| Edition: |
1st |
|
| Author: |
ASHP |
|
|
Specialties:
|
Pharmacy |
|
| Publisher: |
ASHP |
|
4500 East West Highway |
|
Bethesda, MD 20814 |
|
UNITED STATES |
|
P: 866-279-0681 |
|
http://store.ashp.org |
|
| List Price: |
$468.00 |
|
| Google: |
|
|
|
|
|
|
|
At A Glance
|
AHFS Drug Information 2023 contains the most dependable drug information available - all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses. With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice. Updates in the new edition: - Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines
- The latest information on COVID-19 vaccines and therapeutics, including information from FDA Emergency Use Authorizations (EUAs), clinical considerations from the US Centers for Disease Control and Prevention (CDC), and guidelines from the Infectious Diseases Society of America (IDSA) and the National Institutes of Health (NIH)
- Contemporary topics such as new antimigraine treatments, specialty pharmacy drugs, and the antiviral used for treatment of Mpox
- Inclusion of Standardize4Safety concentration standards for IV and oral liquid drugs
- Newly published information on breakthrough oncology drugs approved as part of the FDA?s accelerated approval program
- Expanded content on off-label uses, real-world data, and long-term clinical data
- Updated information on pharmacogenomic considerations based on recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
- Addition of 21 new molecular entities (NMEs) or new therapeutic biological products approved since January 2022
Learn more and order here.
|
|
Reviewer:
|
Yen Dang,
PharmD
(University of Maryland Eastern Shore)
|
|
|
Range
|
Question
|
Score
|
| 1-10 |
Are the author's objectives met? |
10 |
| 1-10 |
Rate the worthiness of those objectives. |
10 |
| 1-5 |
Is this written at an appropriate level? |
5 |
| 1-5 |
Is there significant duplication? (1=significant, 5=insignificant) |
4 |
| 1-5 |
Are there significant omissions? (1=significant, 5=insignificant) |
5 |
| 1-5 |
Rate the authority of the authors. |
5 |
| 1-5 |
Are there sufficient illustrations? |
N/A |
| 1-5 |
Rate the pedagogic value of the illustrations. |
N/A |
| 1-5 |
Rate the print quality of the illustrations. |
N/A |
| 1-5 |
Are there sufficient references? |
N/A |
| 1-5 |
Rate the currency of the references. |
N/A |
| 1-5 |
Rate the pertinence of the references. |
N/A |
| 1-5 |
Rate the helpfulness of the index. |
4 |
| 1-5 |
If important in this specialty, rate the physical appearance of the book |
N/A |
| 1-10 |
Is this a worthwhile contribution to the field? |
10 |
| 1-10 |
If this is a 2nd or later edition, is this new edition needed? |
10 |
|
|
|
Reviewer:
|
Yen Dang,
PharmD
(University of Maryland Eastern Shore)
|
|
|
Description
|
| This book covers comprehensive information on the safety and efficacy of drugs. AHFS DI is the longest published, federally designated drug compendium in the United States issued by a scientific and professional society. The book is written by pharmacists and reviewed by over 500 experts to contain the most up-to-date, evidence-based drug information with therapeutic guidelines and off-label uses. This edition was published in 2023. |
|
|
Purpose
|
| The mission of this book is to provide an evidence-based foundation for safe and effective drug therapy. The book meets its objective as it has a long-standing history of rigorous science-based editorial processes supported by more than 97,000 references. The information provided is objective and free from the influence of pharmaceutical companies as the editorial decisions are evidence-based and made independent of these third parties. |
|
|
Audience
|
| The book is written for pharmacists and other healthcare providers to access specific guidance needed to prescribe and monitor drug therapy safely and effectively. It includes over 97,000 cited references linked to 735,000 statements with 70,000 supporting evidence sources. Using an independent, evidence-based evaluative process, the drug monographs incorporate information from pertinent references in the literature and expert therapeutic guidelines. This point-by-point analysis and evaluation of the literature makes this reference comprehensive, evaluative, and unbiased. |
|
|
Features
|
| The drug monographs are arranged by the AHFS Pharmacologic-Therapeutic Classification to provide readers with an easy review of information on a group of drugs with similar activity. Within each subclass, the monographs are arranged alphabetically by generic name. The monographs contain an introductory description, risk evaluation and mitigation strategies (REMS), dosage and administration, cautions, acute and chronic toxicity, drug interactions, laboratory test inferences, pharmacology, mechanism of action, spectrum, resistance, pharmacokinetics, chemistry and stability, preparations, and references. Both labeled and off-labeled drug uses are included. Each monograph is organized such that the most clinically relevant and frequently sought information appears at the beginning. |
|
|
Assessment
|
| This book is a valuable reference to access drug information, from current therapeutic guidelines to off-label uses. The updates in the 2023 reference contain the latest information about COVID-19 vaccines and therapeutics, contemporary treatment topics, Standardize 4 Safety concentration standards for IV and oral liquid drugs, breakthrough oncology drugs approved through the FDA's accelerated approval program, and pharmacogenomic considerations. The updates also contain clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines. |
|
|
|
|
|
|
|
|
